May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
A run of bad news leaves investors questioning Wave Life Sciences’ ability to deliver on its promises.
Filgotinib could be the safest Jak inhibitor yet, but Galapagos will need to make the most of this as it squares up to Abbvie.
A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
Duchenne muscular dystrophy attracts a new entrant in pamrevlumab, while Alnylam awaits more pivotal data with givosiran.
Keenly awaited results from the first trial of MYO-101 broadly beat expectations, leading Sarepta to buy the gene therapy’s originator.
Galapagos will discover if filgotinib can hang on to its reputation as one of the safest Jak inhibitors in the industry, while Cara is itching for pivotal trial success…
Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.
A limb-girdle muscular dystrophy gene therapy Sarepta licensed last year faces its first clinical test.